ArticleCureus2025
Primary Central Nervous System Lymphoma Associated With Immune Deficiency and Dysregulation: Challenges in Treatment and Management.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lymphomas associated with immune deficiency and dysregulation (IDD) rarely occur in the central nervous system (CNS). Discontinuing immunosuppressives is the first choice of treatment, but it is often not feasible after solid organ transplantation (SOT). We report a case of primary CNS lymphoma (PCNSL) arising in IDD with an unusual clinical course. A 47-year-old woman with a history of chronic use of immunosuppressives after a kidney transplantation presented with a one-month history of headaches and left-sided weakness for two days. Gadolinium (Gd)-enhanced MRI of the brain revealed a mass lesion with ring enhancement in the right basal ganglia, and diffusion-weighted imaging (DWI) confirmed cerebral infarction in the right corona radiata. All blood tumor markers were negative, but cerebrospinal fluid analysis showed a highly elevated β2-microgrobulin (MG). PET showed relatively high 18F-fluorodeoxyglucose (FDG) uptake within the area of ring enhancement on MRI, but no obvious accumulations in tissues outside the CNS. The history and results of laboratory examinations and imaging studies suggested an initial diagnosis of malignant lymphoma. Following resection, the lesion was diagnosed histologically as diffuse large B-cell lymphoma (DLBCL). The tumor was negative for Epstein-Barr virus (EBV)-encoded small RNA; however, blood tests confirmed the presence of EBV-DNA (2.81 LogIU/mL). As the immunosuppressive therapy could not be discontinued, rituximab was initiated on the day after surgery. However, the lesion progressed rather than regressed, and postoperative radiation treatment was administered. MRI four months after surgery showed tumor shrinkage. CNS lymphoma arising in IDD should be considered when a mass lesion develops during long-term immunosuppressive therapy after transplantation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.